Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized,controlled, open-label,phase IV trial

ObjectivesThis study aimed to evaluate the immunogenicity and safety of a hepatitis E (HE) vaccine using an accelerated vaccination schedule (vaccine doses at 0, 7 and 21 days).MethodsA total of 126 participants aged ≥18 years were randomly assigned to receive the hepatitis E virus vaccine in either the accelerated group (0, 7 and 21 days) or the routine group (0, 1 and 6 months). Serology samples were obtained at 0, 21, 28 and 51 days, and 7 months in the accelerated group, or 0, 1, 2 and 7 months in the routine group after the first vaccine injection. Adverse events (AEs) reported during the whole study were analysed.ResultsA total of 126 participants were randomized, 63 for each group. Sixty-two participants in the accelerated group and 63 in the routine group received at least one dose of vaccine; 57 and 63 participants received all three doses and were included in per-protocol set, respectively. In the per-protocol population, at 1 month after the last dose (accelerated group at 51 days versus routine group at 7 months), the seropositive rates were both 100% (57/57 and 63/63, respectively), and the geometric mean concentrations (GMCs) were 8.51 WHO units/mL (95% CI 6.73–10.76) in the accelerated group and 9.67 WHO units/mL (95% CI 7.67–12.20) in the routine group. The ratio of the accelerated group GMC to the routine group GMC was 0.88 (95% CI 0.61–2.17, lower limit of 95% CI > 0.5), indicating that the accelerated vaccination schedule was non-inferior to the routine one. The overall incidence rates of solicited AEs in the accelerated and routine groups were 32.26% (20/62) and 30.16% (19/63), respectively (p 0.800). Most AEs were moderate.ConclusionsAn accelerated schedule is safe and provides protective antibodies in a shorter time compared with the routine schedule. The accelerated schedule should be recommended to adults who are travelling on short notice to an HE-endemic area or during an HE outbreak (Clinical Trial Registration. NCT03168412)     

“施今墨对药”“吕景山对穴”组方治疗失眠59例临床观察

目的研究“施今墨对药”“吕景山对穴”组方治疗失眠的疗效。方法118例门诊患者随机分为两组，其中对照组单纯采用方剂酸枣仁汤加减治疗，治疗组采用“施今墨对药”“吕景山对穴”组方治疗。3个疗程后统计疗效。结果对照组治疗后总有效率为72．88％，睡眠时间为（5．17±0．20）h，治疗组总有效率为91．53％，睡眠时间为（6．72±0．15）h，两组患者治疗后疗效及睡眠时间经统计学分析，差异有统计学意义（P〈0．05）。结论“施今墨对药”“吕景山对穴”组方治疗失眠，疗效显著，且远期疗效较好。     

仁和健太易酵素对人体T淋巴细胞和免疫球蛋白的影响

目的 探究仁和健太易酵素对人体T淋巴细胞和免疫球蛋白的影响,评价中药酵素对提高人体免疫力的作用.方法 采用组间和试验前后对照设计比较法,按剂量口服仁和健太易酵素90 d,以白细胞计数、人体外周血T淋巴细胞亚群CD4/CD8值和人体血清中免疫球蛋白IgG、IgA、IgM的含量为指标,临床观察该酵素对人体免疫力的作用.结果...     

吕仁和教授治疗慢性肾炎经验

慢性肾炎为难治病之一,总结了著名中医肾病专家吕仁和教授的多年临床经验,对慢性肾炎的病因、病机转化及其分期辨治方案和方药进行了详细介绍,对于指导临床治疗与研究有一定意义。     

Role of HIV-2 envelope in Lv2-mediated restriction

We have characterized envelope protein pseudotyped HIV-2 particles derived from two HIV-2 isolates termed prCBL23 and CBL23 in order to define the role of the envelope protein for the Lv2-mediated restriction to infection. Previously, it has been described that the primary isolate prCBL23 is restricted to infection of several human cell types, whereas the T cell line adapted isolate CBL23 is not restricted in these cell types. Molecular cloning of the two isolates revealed that the env and the gag gene are responsible for the observed phenotype and that this restriction is mediated by Lv2, which is distinct from Ref1/Lv1 (Schmitz, C., Marchant, D., Neil, S.J., Aubin, K., Reuter, S., Dittmar, M.T., McKnight, A., Kizhatil, K., Albritton, L.M., 2004. Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J. Virol. 78 (4), 2006-2016). We generated pseudotyped viruses consisting of HIV-2 (ROD-ADeltaenv-GFP, ROD-ADeltaenv-RFP, or ROD-ADeltaenv-REN) and the prCBL23 or CBL23 envelope proteins as well as chimeric proteins between these envelopes. We demonstrate that a single amino acid exchange at position 74 in the surface unit of CBL23-Env confers restriction to infection. This single point mutation causes tighter CD4 binding, resulting in a less efficient fusion into the cytosol of the restricted cell line. Prevention of endosome formation and prevention of endosome acidification enhance infectivity of the restricted particles for GHOST/X4 cells indicating a degradative lysosomal pathway as a cause for the reduced cytosolic entry. The described restriction to infection of the primary isolate prCBL23 is therefore largely caused by an entry defect. A remaining restriction to infection (19-fold) is preserved when endosomal acidification is prevented. This restriction to infection is also dependent on the presence of the point mutation at position 74 (G74E).     

驴胶补血颗粒中微量铁的含量测定

目的:测定驴胶补血颗粒中微量元素Fe的含量。方法:取驴胶补血颗粒,采用湿法消化(HNO3、HClO4),以邻二氮菲为显色剂,用紫外分光光度法测定Fe的含量,方法快速、简便、准确。结果:驴胶补血颗粒中确含有微量的铁元素。结论:实验结果提供了驴胶补血颗粒中微量元素铁的含量的数据,对驴胶补血颗粒的功效又是一大补充。     

吕仁和教授“六对论治”糖尿病性腹泻经验

吕仁和教授认为,糖尿病性腹泻的发生首先责之于先天脾脏功能异常,其发病不仅与湿邪相关,尚与血瘀关系密切,并且血瘀病机始终贯穿于糖尿病性腹泻发生、发展的始终.临证时常用“六对论治”方法治疗糖尿病性腹泻,“六对论治”方法具体包括对病论治、对病辨证论治、对病分期辨证论治、对症论治、对症辨证论治、对症辨病与辨证论治相结合.     

吕仁和教授分期辨治糖尿病学术思想探微

文章通过对吕仁和教授对糖尿病(消渴病)的内涵、表现、演变规律及治疗方法的学术思想的疏理,结合吕老师临证医话,初步探索和分析了吕仁和教授分期辨证治疗糖尿病学术思想、方法和经验,特别是吕仁和教授提出的脾瘅期、消渴期、消瘅期分期思想、"微型癥瘕"病机理论和治则治法,既是对《黄帝内经》理论的发掘和弘扬,又切合现代糖尿病诊断和治疗理念,对拓展糖尿病及其并发症的中医诊治思路很有指导意义。     

食道心房起搏多普勒负荷超声对冠心病左室舒张功能的评价

目的应用起搏负荷超声评价冠心病左室舒张功能的改变。方法使用心脏程序刺激仪,提高心率至次极量,应用彩色多普勒超声心动仪检测肺静脉血流频谱的改变。结果正常人肺静脉血流收缩指数(SF)>50%,肺静脉返流速度(V_(AR))<30cm/s,而冠心病组SF<40%,V_(AR)>40cm/s。结论肺静脉血流参数能较好地评价冠心病左室舒张功能状态。